JP6882184B2 - 多価ｂ型肝炎ウイルス抗原結合分子およびその使用 - Google Patents

多価ｂ型肝炎ウイルス抗原結合分子およびその使用 Download PDF

Info

Publication number
JP6882184B2
JP6882184B2 JP2017549723A JP2017549723A JP6882184B2 JP 6882184 B2 JP6882184 B2 JP 6882184B2 JP 2017549723 A JP2017549723 A JP 2017549723A JP 2017549723 A JP2017549723 A JP 2017549723A JP 6882184 B2 JP6882184 B2 JP 6882184B2
Authority
JP
Japan
Prior art keywords
seq
binding
hbv
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017549723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513680A (ja
JP2018513680A5 (enExample
Inventor
スティーブン エフ． キャロル
スティーブン エフ． キャロル
ラメシュ バリガ
ラメシュ バリガ
ディーン エング
ディーン エング
ブルース エイ． ケイト
ブルース エイ． ケイト
Original Assignee
アイジーエム バイオサイエンシズ インコーポレイテッド
アイジーエム バイオサイエンシズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイジーエム バイオサイエンシズ インコーポレイテッド, アイジーエム バイオサイエンシズ インコーポレイテッド filed Critical アイジーエム バイオサイエンシズ インコーポレイテッド
Publication of JP2018513680A publication Critical patent/JP2018513680A/ja
Publication of JP2018513680A5 publication Critical patent/JP2018513680A5/ja
Application granted granted Critical
Publication of JP6882184B2 publication Critical patent/JP6882184B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
JP2017549723A 2015-03-25 2016-03-25 多価ｂ型肝炎ウイルス抗原結合分子およびその使用 Expired - Fee Related JP6882184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562137881P 2015-03-25 2015-03-25
US62/137,881 2015-03-25
PCT/US2016/024348 WO2016154593A1 (en) 2015-03-25 2016-03-25 Multi-valent hepatitis b virus antigen binding molecules and uses thereof

Publications (3)

Publication Number Publication Date
JP2018513680A JP2018513680A (ja) 2018-05-31
JP2018513680A5 JP2018513680A5 (enExample) 2019-05-09
JP6882184B2 true JP6882184B2 (ja) 2021-06-02

Family

ID=56977811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549723A Expired - Fee Related JP6882184B2 (ja) 2015-03-25 2016-03-25 多価ｂ型肝炎ウイルス抗原結合分子およびその使用

Country Status (8)

Country Link
US (2) US10604559B2 (enExample)
EP (1) EP3274051A4 (enExample)
JP (1) JP6882184B2 (enExample)
KR (1) KR102558839B1 (enExample)
CN (1) CN107921285B (enExample)
AU (1) AU2016238246B2 (enExample)
CA (1) CA2980751A1 (enExample)
WO (1) WO2016154593A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
KR102378289B1 (ko) 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
NZ762365A (en) 2015-03-04 2024-11-29 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
PL3355913T3 (pl) 2015-09-30 2025-02-17 Igm Biosciences, Inc. Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
EP3870223A4 (en) * 2018-10-23 2022-08-24 IGM Biosciences, Inc. MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES
US20230250192A1 (en) * 2019-05-15 2023-08-10 Kymab Limited Improved lambda antibodies
CA3147291A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
EP4188951A4 (en) * 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
US20240209068A1 (en) * 2021-04-01 2024-06-27 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
WO2022265264A1 (ko) * 2021-06-15 2022-12-22 에이피트바이오 주식회사 B형 간염바이러스 pres1항원의 간세포 수용체 결합부위에 특이적으로 결합하는 인간 항체 및 이의 용도
US20240391979A1 (en) * 2021-09-13 2024-11-28 Achelois Biopharma, Inc. Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CN116640208B (zh) * 2023-06-01 2025-02-07 重庆医科大学 一种乙肝核心抗原单链抗体噬菌体文库及其构建与应用
CN117624340B (zh) * 2024-01-23 2024-04-30 北京臻知医学科技有限责任公司 识别人乙型肝炎病毒（hbv）抗原的t细胞受体（tcr）及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
JPS6358260A (ja) * 1986-08-29 1988-03-14 Chemo Sero Therapeut Res Inst ＩｇＭ型抗体の測定法
US5061619A (en) * 1987-11-05 1991-10-29 Connaught Laboratories Limited Immunoassay using antibody-antigen conjugates
CA2064972A1 (en) 1991-04-03 1992-10-04 John Joseph Rejman Immunoassay for immunoglobulins
GB9401987D0 (en) 1994-02-02 1994-03-30 Imperial College Modified nucleic acid
US6417324B1 (en) * 2000-04-21 2002-07-09 Tripep Ab Synthetic peptides that bind to the hepatitis B virus core and e antigens
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
KR100345463B1 (ko) 1998-11-19 2003-01-08 주)녹십자 B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
ATE490787T1 (de) * 2003-07-15 2010-12-15 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm- produktion
CN1600856A (zh) * 2003-09-26 2005-03-30 陕西九州科技股份有限公司 分泌抗乙肝人单克隆抗体的异种杂交瘤细胞系的构建方法
AU2005304973A1 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
ATE529436T1 (de) 2007-04-20 2011-11-15 Hoffmann La Roche Erkennung von primären infektionen mit krankheitserregern
WO2011045079A1 (en) 2009-10-15 2011-04-21 Intercell Ag Hepatitis b virus specific human antibodies
CN102321720B (zh) * 2011-07-28 2014-09-03 万晓春 一种混合细胞培养生产纯人源单克隆抗体的方法
EP2760891B1 (en) 2011-09-26 2018-11-07 JN Biosciences LLC Hybrid constant regions
ES2735289T3 (es) 2012-02-08 2019-12-17 Igm Biosciences Inc Proteínas de unión a cdim y usos de las mismas
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
KR20150070181A (ko) 2012-09-27 2015-06-24 크루셀 홀란드 비.브이. B형 간염 바이러스에 결합하고 이를 중화시킬 수 있는 인간 결합 분자 및 그의 용도
CN105722855B (zh) 2013-09-05 2021-04-23 Igm生物科学股份有限公司 恒定链经修饰的双特异性五价和六价Ig-M抗体
SG11201605691VA (en) 2014-01-16 2016-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
KR102378289B1 (ko) 2014-02-10 2022-03-23 아이쥐엠 바이오사이언스 인코포레이티드 IgA 다중-특이적 결합 분자
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
CA2972990A1 (en) 2015-01-20 2016-07-28 Beatrice Tien-Yi WANG Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
NZ762365A (en) * 2015-03-04 2024-11-29 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
PL3355913T3 (pl) 2015-09-30 2025-02-17 Igm Biosciences, Inc. Cząsteczki wiążące ze zmodyfikowanym łańcuchem j
WO2017059387A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
DK3455257T3 (da) 2016-05-09 2021-11-01 Igm Biosciences Inc Anti-pd-l1-antistoffer
EP3487298A4 (en) 2016-07-20 2020-03-11 IGM Biosciences, Inc. MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF
WO2018017763A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
MX2019000796A (es) 2016-07-20 2019-06-03 Igm Biosciences Inc Moleculas multimericas de union a ox40 y usos de las mismas.
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
KR102696143B1 (ko) 2017-04-07 2024-08-21 아이쥐엠 바이오사이언스 인코포레이티드 보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
CN111757941A (zh) 2018-02-26 2020-10-09 Igm生物科学股份有限公司 多聚体抗dr5结合分子与化学治疗剂联合用于治疗癌症的用途
MX2020009069A (es) 2018-03-01 2020-10-08 Igm Biosciences Inc Mutaciones de fc de igm y de la cadena j que afectan la semivida de igm en suero.
EP3870223A4 (en) 2018-10-23 2022-08-24 IGM Biosciences, Inc. MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES
WO2020163646A1 (en) 2019-02-08 2020-08-13 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CA3147291A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
WO2021034646A1 (en) 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
US20220306760A1 (en) 2019-08-23 2022-09-29 Igm Biosciences, Inc. Igm glycovariants
WO2021055765A2 (en) 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
KR20220122699A (ko) 2020-01-06 2022-09-02 아이쥐엠 바이오사이언스 인코포레이티드 고도로 시알릴화된 다량체 결합 분자
EP4139362A2 (en) 2020-04-22 2023-03-01 IGM Biosciences Inc. Pd-1 agonist multimeric binding molecules
JP2023526224A (ja) 2020-05-12 2023-06-21 アイジーエム バイオサイエンシズ インコーポレイテッド がんを治療するための、がん治療薬との組合せでの多量体抗ｄｒ５結合分子の使用
EP4188951A4 (en) 2020-07-27 2024-08-28 IGM Biosciences, Inc. Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies

Also Published As

Publication number Publication date
KR102558839B1 (ko) 2023-07-25
EP3274051A1 (en) 2018-01-31
US20210002353A1 (en) 2021-01-07
US10604559B2 (en) 2020-03-31
US20180118814A1 (en) 2018-05-03
CN107921285A (zh) 2018-04-17
US11535664B2 (en) 2022-12-27
AU2016238246B2 (en) 2021-05-13
JP2018513680A (ja) 2018-05-31
KR20180012245A (ko) 2018-02-05
CA2980751A1 (en) 2016-09-29
WO2016154593A1 (en) 2016-09-29
CN107921285B (zh) 2022-06-07
AU2016238246A1 (en) 2017-10-12
EP3274051A4 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
US11535664B2 (en) Multi-valent hepatitis B virus antigen binding molecules and uses thereof
JP7796918B2 (ja) エボラウイルス糖タンパク質に対するヒト抗体
JP7297814B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
JP6811723B2 (ja) 多価ヒト免疫不全ウイルス抗原結合分子およびその使用方法
US12304946B2 (en) Antibodies that neutralize hepatitis B virus and uses thereof
EP3094644B1 (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
JP2019528050A (ja) 抗ジカ（ｚｉｋａ）ウイルス抗体およびその使用方法
AU2020336980B2 (en) Antibody compositions and methods for treating hepatitis B virus infection
NZ725965A (en) Method for biocatalytic whole cell reduction of dehydrocholic acid compounds, and 7-beta-hydroxysteroid dehydrogenase mutants
US20240092872A1 (en) Compositions and methods for treating hepatitis b virus infection
JP2025525416A (ja) ＨＢＶ表面抗原（ＨＢｓＡｇ）およびＣＤ３に対する二重特異性抗体ならびにその使用
HK40056051A (en) Antibodies that neutralize hepatitis b virus and uses thereof
OA18324A (en) Human antibodies to Ebola virus glycoprotein.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180307

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200312

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882184

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees